Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control
Health Science Reports2022Vol. 6(1), pp. e980–e980
Citations Over Time
Hala Joharji, Delal Alkortas, Aziza Ajlan, Mohamed O. Ahmed, Hamad I. Al‐Ashgar, Mohammed Alquaiz, Dieter Broering, Mohammed Al‐Sebayel, Hussien Elsiesy, Faisal Aba Alkhail, Waleed K. Al‐Hamoudi, Edward De Vol, Epi Amirah Almuhayshir, Ahmed Al‐Jedai
Abstract
Generic sofosbuvir combined with branded daclatasvir was safe and effective for treating genotype 4 HCV compared to Sof-Led. This combination may significantly reduce the cost burden, enabling a larger pool of treated patients. Office of research affairs at KFSHRC RAC# 2171 036.
Related Papers
- → Hepatitis C virus NS5A inhibitors and drug resistance mutations(2014)126 cited
- → The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir(2018)19 cited
- → Effect of Minor Populations of NS5A and NS5B Resistance-Associated Variants on HCV Genotype-3 Response to Daclatasvir plus Sofosbuvir, with or without Ribavirin(2016)23 cited
- → Ledipasvir/sofosbuvir fixed-dose combination for treatment ofhepatitis C virus genotype 4 infection(2016)3 cited
- → Sofosbuvir: The Discovery of a Curative Therapy for the Treatment of Hepatitis C Virus(2016)11 cited